Company Filing History:
Years Active: 2023-2025
Title: The Innovations of Jeffrey Zuber
Introduction
Jeffrey Zuber is an accomplished inventor based in Somerville, MA (US). He has made significant contributions to the field of biotechnology, particularly in the development of RNA interference (RNAi) technologies. With a total of two patents to his name, Zuber's work focuses on innovative methods for treating diseases associated with specific gene expressions.
Latest Patents
Zuber's latest patents include groundbreaking inventions that target critical genes involved in various health conditions. The first patent, titled "Cell death-inducing DFFA-like effector B (CIDEB) iRNA compositions and methods of use thereof," relates to double-stranded ribonucleic acid (dsRNA) compositions that specifically target the CIDEB gene. This invention outlines methods for inhibiting the expression of CIDEB and offers potential treatments for subjects suffering from CIDEB-associated diseases or disorders.
The second patent, "Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof," focuses on RNAi agents that target the ANGPTL3 gene. This invention provides methods for using these RNAi agents to inhibit ANGPTL3 expression and offers therapeutic approaches for disorders related to lipid metabolism, such as hyperlipidemia and hypertriglyceridemia.
Career Highlights
Jeffrey Zuber is currently employed at Alnylam Pharmaceuticals, Inc., a leading company in the field of RNAi therapeutics. His work at Alnylam has positioned him at the forefront of innovative research aimed at developing novel treatments for various genetic disorders. Zuber's expertise in RNAi technology has made him a valuable asset to the company and the broader scientific community.
Collaborations
Throughout his career, Zuber has collaborated with notable colleagues, including Mark K Schlegel and Lucas D BonDurant. These collaborations have fostered a dynamic research environment, allowing for the exchange of ideas and the advancement of innovative solutions in biotechnology.
Conclusion
Jeffrey Zuber's contributions to the field of biotechnology through his patents and work at Alnylam Pharmaceuticals highlight his commitment to advancing medical science. His innovative approaches to gene-targeting therapies have the potential to transform treatment options for patients with genetic disorders.